

Liheng Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3504696/publications.pdf>

Version: 2024-02-01

38
papers

514
citations

623734

14
h-index

752698

20
g-index

38
all docs

38
docs citations

38
times ranked

669
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different <sc>CYP2D6</sc> genotypes: A propensity score matched cohort study. <i>International Journal of Cancer</i> , 2022, 150, 1664-1676.	5.1	4
2	Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002) A randomized multicentre, open-label, phase 3 Trial. <i>Cancer Research</i> , 2022, 82, P2-12-02-P2-12-02.	0.9	0
3	Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 3677-3685.	7.0	14
4	Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 604319.	2.8	10
5	A Positive Feedback Loop of Long Noncoding RNA LINC00152 and KLF5 Facilitates Breast Cancer Growth. <i>Frontiers in Oncology</i> , 2021, 11, 619915.	2.8	11
6	Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting. <i>Gland Surgery</i> , 2021, 10, 1899-1909.	1.1	0
7	LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 205.	8.6	20
8	Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway. <i>Journal of Translational Medicine</i> , 2021, 19, 344.	4.4	10
9	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. <i>EClinicalMedicine</i> , 2021, 38, 101031.	7.1	2
10	Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. <i>EBioMedicine</i> , 2021, 71, 103560.	6.1	62
11	HIF1 β Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 729965.	3.7	5
12	Ultrasound-Guided Breast Biopsy: Improved Accuracy of 10-G Cable-Free Elite Compared With 14-G CCNB. <i>Journal of Surgical Research</i> , 2020, 247, 172-179.	1.6	5
13	Long Noncoding RNA DANCR Regulates Cell Proliferation by Stabilizing SOX2 mRNA in Nasopharyngeal Carcinoma. <i>American Journal of Pathology</i> , 2020, 190, 2343-2354.	3.8	8
14	Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094088.	3.2	3
15	SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1230.	2.8	6
16	The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer. <i>Gland Surgery</i> , 2020, 9, 925-935.	1.1	2
17	Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 631.	2.8	17
18	Upregulation of microRNA-1 inhibits proliferation and metastasis of breast cancer. <i>Molecular Medicine Reports</i> , 2020, 22, 454-464.	2.4	21

#	ARTICLE	IF	CITATIONS
19	Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting. <i>International Journal of Biological Markers</i> , 2020, 35, 38-49.	1.8	1
20	Association of lncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer. <i>BMC Cancer</i> , 2019, 19, 877.	2.6	30
21	Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. <i>Future Oncology</i> , 2019, 15, 1781-1789.	2.4	1
22	Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. <i>Cancer Biology and Therapy</i> , 2019, 20, 941-947.	3.4	15
23	Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy. <i>Cancer Cell International</i> , 2019, 19, 78.	4.1	10
24	Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer. <i>Gland Surgery</i> , 2019, 8, 627-635.	1.1	6
25	Predictive and prognostic value of prognostic nutritional index for locally advanced breast cancer. <i>Gland Surgery</i> , 2019, 8, 618-626.	1.1	17
26	DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. <i>Cancer Letters</i> , 2019, 442, 242-251.	7.2	44
27	Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer. <i>Epigenomics</i> , 2019, 11, 297-321.	2.1	25
28	Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 138-138.	1.7	7
29	Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1748-1759.	0.0	7
30	The ubiquitin-specific protease USP8 deubiquitinates and stabilizes Cx43. <i>Journal of Biological Chemistry</i> , 2018, 293, 8275-8284.	3.4	23
31	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 201-206.	1.8	5
32	Clinical significance of quantitative $HER2$ gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 801-808.	2.0	21
33	Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. <i>Cell Death Discovery</i> , 2018, 4, 21.	4.7	28
34	Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. <i>Oncotarget</i> , 2017, 8, 79305-79314.	1.8	26
35	Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics. <i>Cancer Management and Research</i> , 2017, Volume 9, 891-901.	1.9	26
36	Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes. <i>OncoTargets and Therapy</i> , 2015, 8, 2665.	2.0	2

#	ARTICLE	IF	CITATIONS
37	Prognostic effect of menstrual cycle on timing of surgery in premenopausal breast cancer patients. American Journal of Surgery, 2015, 210, 506-511.	1.8	3
38	Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer. Current Medical Research and Opinion, 2014, 30, 1337-1344.	1.9	17